

Martina Curto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5307926/martina-curto-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	1,142 citations	20 h-index	30 g-index
67 ext. papers	1,394 ext. citations	5.2 avg, IF	4.28 L-index

#	Paper	IF	Citations
64	School Refusal Behavior: Role of Personality Styles, Social Functioning, and Psychiatric Symptoms in a Sample of Adolescent Help-Seekers. 2022 , 19, 20-28		
63	Ubrogepant. <i>Headache</i> , 2022 , 43-50	0.2	
62	Psychotropic Drugs Levels in Seminal Fluid: A New Therapeutic Drug Monitoring Analysis?. <i>Frontiers in Endocrinology</i> , 2021 , 12, 620936	5.7	0
61	Cluster Headache is Still Lurking in the Shadows. <i>Pain and Therapy</i> , 2021 , 10, 777-781	3.6	2
60	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 249-254	4.3	1
59	Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021 , 1867, 166042	6.9	18
58	Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1143-1155	4	2
57	The Trace Kynurenine, Cinnabaric Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020 , 46, 1471-1481	1.3	8
56	Ubrogepant for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 755-759	4	16
55	Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	16
54	Profiling lasmiditan as a treatment option for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 147-153	4	15
53	Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings. <i>Current Psychopharmacology</i> , 2019 , 8, 238-243	0.6	1
52	Fremanezumab for the preventive treatment of migraine in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 741-748	3.8	12
51	Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis. <i>Schizophrenia Research</i> , 2019 , 208, 465-466	3.6	5
50	Tryptophan and Kynurenine Metabolites: Are They Related to Depression?. <i>Neuropsychobiology</i> , 2019 , 77, 23-28	4	16
49	Dialectical behaviour therapy (DBT) for forensic psychiatric patients: An Italian pilot study. <i>Criminal Behaviour and Mental Health</i> , 2019 , 29, 122-130	1.4	13
48	Efficacy of the Cooperative Assessment Method (COOPAS) to Improve the Psychiatric Care of Help-Seeking Adolescents. 2019 , 16, 189-196		1

47	A novel SCL-90-R six-item factor identifies subjects at risk of early adverse outcomes in public mental health settings. <i>Psychiatry Research</i> , 2018 , 267, 376-381	9.9	2
46	Depressive symptoms, temperament/character, and attention deficit/hyperactivity disorder traits in medical students seeking counseling. <i>Psychiatria Danubina</i> , 2018 , 30, 305-309	1.8	4
45	Pharmacogenetic considerations for migraine therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1161-1167	5.5	9
44	Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. <i>Neuropharmacology</i> , 2017 , 112, 365-372	5.5	36
43	Increased Total Urinary Cortisol (tUC) and Serum Brain-derived Neurotrophic Factor (BDNF) Ratio in Alzheimer Disease (AD)-affected Patients. <i>Alzheimer Disease and Associated Disorders</i> , 2017 , 31, 173-176 ^{2.5}		13
42	Lasmiditan for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 227-234	5.9	29
41	The Italian version of the 92-item Prodromal Questionnaire: Concurrent validity with the SIPS and factor analysis in a sample of 258 outpatients aged 11-36years. <i>Schizophrenia Research</i> , 2017 , 189, 50-56 ^{3.6}		11
40	Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment. <i>Psychiatry Research</i> , 2017 , 251, 294-297	9.9	1
39	LC-MS/MS simultaneous analysis of allopregnanolone, epiallopregnanolone, pregnanolone, dehydroepiandrosterone and dehydroepiandrosterone 3-sulfate in human plasma. <i>Bioanalysis</i> , 2017 , 9, 527-539	2.1	7
38	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , 2017 , 253, 296-302	9.9	9
37	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017 , 19, 32	4.4	13
36	Psychiatric Comorbidity in Migraine and Chronic Headache. <i>Headache</i> , 2017 , 23-40	0.2	
35	Executive functions in obsessive-compulsive disorder: An activation likelihood estimate meta-analysis of fMRI studies. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 378-93	3.8	24
34	Interpersonal sensitivity and functioning impairment in youth at ultra-high risk for psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 7-16	5.5	20
33	Headache: Cluster headache treatment - RCTs versus real-world evidence. <i>Nature Reviews Neurology</i> , 2016 , 12, 557-8	15	12
32	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 1217-27	4.3	20
31	Anti-CGRP monoclonal antibodies in migraine: current perspectives. <i>Internal and Emergency Medicine</i> , 2016 , 11, 1045-1057	3.7	37
30	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 414-23	6.6	15

29	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 399-406	5.5	27
28	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1011-20	5.5	5
27	Systematic Review of Clozapine Cardiotoxicity. <i>Current Psychiatry Reports</i> , 2016 , 18, 68	9.1	51
26	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015 , 10, 413-21	3.7	17
25	Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels. <i>Psychiatry Research</i> , 2015 , 227, 171-8	9.9	22
24	Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study. <i>Journal of Affective Disorders</i> , 2015 , 174, 57-63	6.6	25
23	Features preceding diagnosis of bipolar versus major depressive disorders. <i>Journal of Affective Disorders</i> , 2015 , 173, 134-42	6.6	24
22	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. <i>Journal of Headache and Pain</i> , 2015 , 17, 27	8.8	32
21	Altered kynurenine pathway metabolites in serum of chronic migraine patients. <i>Journal of Headache and Pain</i> , 2015 , 17, 47	8.8	39
20	Impairment of left ventricular function early in treatment with clozapine: a preliminary study. <i>International Clinical Psychopharmacology</i> , 2015 , 30, 282-9	2.2	14
19	O066. Kynurenine pathway metabolites in cluster headache. <i>Journal of Headache and Pain</i> , 2015 , 16, A87	8.8	0
18	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. <i>Journal of Headache and Pain</i> , 2015 , 17, 1	8.8	93
17	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , 2015 , 4, 826		50
16	The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery. <i>Recent Patents on CNS Drug Discovery</i> , 2015 , 10, 55-64		18
15	Relationship between the Rorschach Perceptual Thinking Index (PTI) and the Positive and Negative Syndrome Scale (PANSS) in psychotic patients: a validity study. <i>Psychiatry Research</i> , 2015 , 225, 315-21	9.9	12
14	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. <i>Scientific Reports</i> , 2015 , 5, 17799	4.9	68
13	Impact of migraine on fibromyalgia symptoms. <i>Journal of Headache and Pain</i> , 2015 , 17, 28	8.8	51
12	Neurocognition in schizophrenia: from prodrome to multi-episode illness. <i>Psychiatry Research</i> , 2014 , 220, 129-34	9.9	43

11	The presence of depressive symptoms in comorbidity with Alzheimer's disease does not influence changes in serum brain-derived neurotrophic factor levels in older patients. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 439-40	3.9	7
10	Self-reported attenuated psychotic-like experiences in help-seeking adolescents and their association with age, functioning and psychopathology. <i>Schizophrenia Research</i> , 2014 , 160, 110-7	3.6	37
9	Validation of the Italian version of interpersonal sensitivity measure (IPSM) in adolescents and young adults. <i>Journal of Affective Disorders</i> , 2014 , 156, 164-70	6.6	12
8	Basic symptoms and psychotic symptoms: their relationships in the at risk mental states, first episode and multi-episode schizophrenia. <i>Comprehensive Psychiatry</i> , 2014 , 55, 785-91	7.3	14
7	Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report. <i>Aging Clinical and Experimental Research</i> , 2014 , 26, 461-4	4.8	23
6	Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013 , 23, 232-4	2.9	3
5	Increased serum Dickkopf-1 levels in drug-abusing psychotic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 36, 239-44	5.5	1
4	Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients. <i>Comprehensive Psychiatry</i> , 2012 , 53, 931-9	7.3	12
3	Re: Response to Anderson's Letter to the Editor. Comment on: Hemochromatosis and bipolar disorder, Serata et al. (2012) <i>Gen Hosp Psychiatry</i> 34(1)101.e1-101.e3. <i>General Hospital Psychiatry</i> , 2012 , 34, 433-435	5.6	
2	Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. <i>Recent Patents on CNS Drug Discovery</i> , 2011 , 6, 196-204		6
1	Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine _{2A} serotonin receptors in the frontal cortex of living mice. <i>Molecular Pharmacology</i> , 2009 , 76, 379-87	4.3	41